Vallejo-Aparicio, Laura Amanda
Molina, Jesús
Ojanguren, Iñigo
Viejo Casas, Ana
Huerta, Alicia
Svedsater, Henrik
Funding for this research was provided by:
GlaxoSmithKline (HO-18-12945)
Article History
Received: 3 December 2018
Accepted: 9 August 2019
First Online: 23 September 2019
Change Date: 4 December 2019
Change Type: Correction
Change Details: In the published article, the Table��1 was published incorrectly.
Compliance with ethical standards
:
: Laura Amanda Vallejo-Aparicio is an employee of GlaxoSmithKlne. Jesús Molina received fees for his involvement in the present analysis, not receiving any payment for writing the manuscript, and has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Roche, AstraZeneca and consulting fees form AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline. Iñigo Ojanguren has received fees for his involvement in the present analysis, not receiving any payment for writing the manuscript, speaker fees from Boehringer Ingelheim, Novartis, TEVA, Astrazeneca and consulting fees form GlaxoSmithKline. Ana Viejo received fees for her involvement in the present analysis, not receiving any payment for writing the manuscript. Alicia Huerta was an employee of GlaxoSmithKline at the time of the analysis. Henrik Svedsater is an employee of and holds stocks of GlaxoSmithKline.